Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
The Journal of Medicinal Chemistry Publishes Study Showing Potential of the Potent EED Inhibitor EEDi-5273 (APG-5918) to Achieve Complete Tumor Regression by Modulating the Epigenetics 2021-10-18 22:42
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China 2021-10-18 20:00
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint 2021-10-18 08:00
AFT Launches NZ-Made, 100% Natural, 90% Recyclable Hemptuary® Skincare Range 2021-10-18 05:00
Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma 2021-10-15 12:44
International Biopharma Industry Week Shanghai 2021 Opens 2021-10-15 12:22
Qiming's Portfolio Company Abbisko Lists on Main Board of HKEx 2021-10-15 12:00
Interim Results Of A Pioneering Combination Study In Argentina With More Than 1,000 Participants Confirm The One-shot Sputnik Light Vaccine (The First Component Of The Sputnik V Vaccine) Is An Effective Universal Booster For Vaccines Produced By AstraZeneca, Sinopharm, Moderna And Cansino Inducing Strong Immune Response And Showing High Safety Profile. Combination Of AstraZeneca And Sputnik Light Vaccines Showed High Immunogenicity Results. 2021-10-15 05:26
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA) 2021-10-14 20:46
A China-developed COVID-19 vaccine is conducting clinical trial in Philippines 2021-10-14 12:58
Gannex Announces Clinical and Preclinical Data of Four NASH Programs to be Presented in Oral or Poster Presentation at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases 2021-10-13 20:30
One-shot Sputnik Light vaccine (first component of the Sputnik V vaccine) demonstrates 70% efficacy against infection with the Delta variant during the first three months after vaccination, Gamaleya Center analysis shows 2021-10-13 20:30
Berry Oncology Releases Latest Research Results on Early Screening for Multiple Cancers 2021-10-13 20:20
I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China 2021-10-13 20:00
Shanghai, industry partners to co-build world-class biopharma industry cluster 2021-10-13 19:43
The CDE Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients 2021-10-13 15:47
Accelerate Innovation Towards the Future，SAB of Winhealth Pharma Formally Established 2021-10-12 23:45
DarwinHealth Announces Scientific Collaboration with Prelude Therapeutics to Develop Novel Biomarkers for Multiple Oncology Candidates 2021-10-12 22:52
Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy 2021-10-12 21:00
CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan 2021-10-12 20:30
1 217 218 219 220 221 413